Clinical Trial Update: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for an autologous tumor vaccine approach using GM-CSF–producing cells and GM.CD40L in mantle cell lymphoma, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• GM-CSF-Producing and GM.CD40L for Autologous Tumor Vaccine

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-09-04